Drug Profile


Alternative Names: Bedoradrine sulfate; KUR-1246; MLN-221; MN-221

Latest Information Update: 08 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kissei Pharmaceutical
  • Developer Kissei Pharmaceutical; MediciNova
  • Class Acetamides; Antiasthmatics; Ethanolamines; Naphthalenes; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Acute asthma
  • Phase I Chronic obstructive pulmonary disease
  • No development reported Preterm labour; Status asthmaticus

Most Recent Events

  • 08 Jun 2016 Phase-I development is ongoing for Chronic obstructive pulmonary disease in USA (Kissei Pharmaceutical pipeline, June 2016)
  • 10 Nov 2015 MediciNova receives patent allowance for bedoradrine in Japan
  • 18 Aug 2015 Phase-II development of Acute asthma is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top